PRECIPIO, INC. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Sales
PRECIPIO, INC. (PRPO) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Sales of $477.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-29.
Discontinued › Income Statement › Other Income
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSales · last filed 2021-03-29
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, sales for the quarter ending 2019-12-31 was $0.00.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, sales for the quarter ending 2019-09-30 was $0.00.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, sales for the quarter ending 2019-06-30 was $438.00K.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, sales for the quarter ending 2019-03-31 was $39.00K.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, sales for fiscal 2019 was $477.00K, a 58.47% increase from fiscal 2018.
- PRECIPIO, INC. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, sales for fiscal 2018 was $301.00K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Sales 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Sales 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Sales 9 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Sales 12 month |
|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $0.00 derived: sum of 2 quarters · filed 2021-03-29 | $438.00K derived: sum of 3 quarters · filed 2021-03-29 | $477.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $438.00K derived: sum of 2 quarters · filed 2020-11-13 | $477.00K 10-Q · filed 2020-11-13 | |
| 2019-06-30 | $438.00K 10-Q · filed 2020-08-13 | $477.00K 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | $39.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $301.00K 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |